Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
ASCO 2018: Novel treatment strategies in prostate cancer therapeutics

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 2898

Prof Karim Fizazi and Dr Neal Shore

Dr Neal Shore speaks to Prof Karim Fizazi at ASCO 2018 about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.

Dr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of 50%).

Trials building on immune checkpoint therapies with novel combinations to improve response rates have shown promise. Among these, the combination of pembrolizumab and enzalutamide is being explored as a doublet or a triplet with the addition of ADXS-PSA in KEYNOTE-046.

Dr Shore raises PARP inhibitors as an avenue of research, with the recent TOPARP trial confirming the activity of olaparib, and Prof Fizazi considers how different genetic abnormalities will inform selection in upcoming trials and eventual care.

PSMA testing, already providing new insights when used in combination with PET imaging, may also offer new inroads in developing treatments, and Prof Fizazi summarises current clinical interest in targeted or radiologic medicine.


Checkpoint immunotherapy for prostate cancers
Heating up immunologically cold tumours
PARP inhibitors for advanced prostate cancer
PSMA testing

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation